
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros is poised for success with its innovative pipeline, potential catalysts through planned drug approvals in 2026, and recent favorable financial results including net income of $86.5 million in the fourth quarter of 2025. The company's recently granted J-code for its newly approved TA-TMA therapy should reduce reimbursement friction and help accelerate demand, a key factor in converting clinical interest into utilization in the orphan disease market. Combined with a strong market need and improved financial profile, Omeros is well-positioned for future growth and potential success for investors.
Bears say
Omeros is facing multiple risk factors, including clinical and regulatory risk, partnership risk, financial risk, commercial risk, legal and intellectual property risk, and market share risk. Although the company has recently announced its first commercial sales and shipments of YARTEMLEA, the first approved therapy for transplant-associated thrombotic microangiopathy, there is still uncertainty surrounding the success of its clinical-stage development programs and the potential for competition in the market. Additionally, the high level of risk involved in the biotechnology industry makes it difficult to accurately predict the company's future financial performance and market share.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares